Skip to content
Study details
Enrolling now

Ketamine for Opioid Use Disorder

University of Maryland, Baltimore
NCT IDNCT06943859ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

50

Study length

about 3.6 years

Ages

18–65

Locations

1 site in MD

About this study

Researchers are testing if ketamine helps reduce opioid cravings in adults starting methadone treatment. The trial also investigates whether low doses of ketamine improve symptoms like depression and pain, and whether it leads to better treatment outcomes compared to a very low dose.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Treatment with Ketamine
  • 2.Take Treatment with Very Low Dose Ketamine
PhasePhase 2
DrugKetamine

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low11%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia), anesthetic (NMDA receptor antagonist; induces dissociative anesthesia and analgesia)

Endpoints

Secondary: Chronic pain ratings, Insomnia Symptoms, Severity of depression symptoms, Sleep quality ratings on a Visual Analogue Scale (VAS)

Body systems

Psychiatry / Mental Health